Immunology
2 drugs are in development for Chronic Inflammatory Demyelinating Polyneuropathy.
- Companies
- 2
- Clinical trials
- 10
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Chronic Inflammatory Demyelinating Polyneuropathy pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Batoclimab | Immunovant, Inc. (IMVT) |
Phase 4(1)
| Drug | Company |
|---|---|
| Efgartigimod PH20 SC | ARGENX SE (ARGX) |
About this indication
Chronic Inflammatory Demyelinating Polyneuropathy context
Immunology·MeSH: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (D020277)
Narrower concept of MeSH descriptor Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Frequently asked questions
How many drugs are in development for Chronic Inflammatory Demyelinating Polyneuropathy?
BioSniper tracks 2 drugs in development for Chronic Inflammatory Demyelinating Polyneuropathy across 2 companies.
How many clinical trials target Chronic Inflammatory Demyelinating Polyneuropathy?
There are 10 clinical trials targeting Chronic Inflammatory Demyelinating Polyneuropathy tracked by BioSniper.